- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06085625
A Randomized Control Trial for Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective:
--To determine whether same-day discharge is non-inferior to usual care (overnight stay) with regard to the MD Anderson Symptom Inventory - Thyroid (MDASI-Thyroid) mean severity score, as assessed at 2 weeks post-procedure in patients undergoing thyroid lobectomy.
Secondary Objectives:
- To determine whether same-day discharge is non-inferior to usual care (overnight stay) with regard to the MDASI-Thyroid mean severity score, as assessed at 24 hours post-procedure in patients undergoing thyroid lobectomy.
- To determine whether the two arms differ by incidence of deviations from normal as defined by post-operative hematoma, emergency care presentation, readmission/re-intervention, high pain severity scores, and 30-day mortality.
- To determine whether morphine milligram equivalents (MME) used over the 2-week post-operative period differs between patients who receive same-day discharge vs. those who receive usual care (overnight stay) after receiving thyroid lobectomy.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Paul Graham, M D
- Phone Number: (832) 829-2547
- Email: phgraham@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
Contact:
- Paul Graham, M D
- Phone Number: 832-829-2547
- Email: phgraham@mdanderson.org
-
Principal Investigator:
- Paul Graham, M D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients ≥18 years of age
- Patients undergoing initial partial or complete thyroid lobectomy
- English and non-English speaking patients are eligible
Exclusion Criteria:
- Increased risk of bleeding (e.g., Aspirin, antiplatelet therapy, or anticoagulation that cannot be held 5 days before surgery, baseline thrombocytopenia <50,000/µL)
- Pre-existing medical comorbidities or poor performance status (Eastern Cooperative Oncology Group performance status >2) that would otherwise dictate overnight in-hospital postoperative observation
- Increased distance of residence from index hospital (>50 miles) or inability to stay within the targeted area (<50 miles) postoperatively prohibiting timely return to the index hospital in emergent situations
- Lives alone or unable to independently perform Activities of Daily Living and no available caregiver in the immediate postoperative period (POD 0-3)
- Pregnant women will not be included in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy
Participants will first complete a survey about the severity of your symptoms. This will be done at your pre-surgery (pre-operative) visit and should take about 5-10 minutes to complete. Study Groups At your pre-surgery visit, you will be assigned to either be sent home on the same day as surgery or to stay in the hospital overnight (or longer) for observation. This will be determined based on which group your surgeon has been assigned to. Participants will be told which group you are in. |
Participants will be asked to complete a survey 3 times (before surgery, after surgery, and 2 weeks after surgery).
You will be monitored for up to 1 month after your surgery, where you may be contacted by a study provider virtually or in person to ask you about medication usage and heath care needs.
After surgery, Participants will complete the same survey as in the pre-surgery visit about 1 day and then 2 weeks after surgery. These surveys will be completed electronically through the MyChart system. They will take about 5-10 minutes to complete and must be done within 24 hours after receiving the survey. Participants will be monitored for 1 month after your surgery, including your standard-of-care postoperative visit at about 2 weeks. You may be contacted by a provider for a phone or in person visit at the 1-month time point to ask how you are doing. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Time Frame: through study completion; an average of 1 year
|
through study completion; an average of 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paul Graham, M D, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-0511
- NCI-2023-08793 (Other Identifier: NCI-CTRP Clinical Trials Registry)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid Lobectomy
-
AesDex, LLCUnknownLobectomy | SegmentectomyUnited Kingdom
-
Gansu Provincial HospitalNot yet recruitingLobectomy | Dexmedetomidine | Dexamethasone | Ropivacaine
-
Ottawa Hospital Research InstituteCompletedLobectomy | Segmentectomy | Pulmonary Air Leak | Wedge ResectionCanada
-
Shanghai Hengrui Pharmaceutical Co., Ltd.RecruitingThoracoscopic LobectomyChina
-
Brigham and Women's HospitalUnknownLung Nodule | VATS Lobectomy | VATS Segmentectomy | Care PathwayUnited States
-
Hospices Civils de LyonUnknownHepatectomy | Lobectomy | PancreaticoduodenectomyFrance
-
Xueying YangUnknownLobectomy | Subxiphoid Uniportal Video-assisted Thoracoscopic SurgeryChina
-
Copenhagen Academy for Medical Education and SimulationCopenhagen University Hospital, DenmarkCompletedLobectomy | Video Assisted Thoracoscopic Surgery | Shared Mental Models | Technical SkillsDenmark
-
Hospices Civils de LyonCompletedWedge Resection | Lobectomy by Video-thoracoscopiesFrance
-
Integra LifeSciences CorporationMedtronic - MITGCompletedLung Disease | Pulmonary LobectomyBelgium, United States, Austria, Netherlands, Switzerland, United Kingdom
Clinical Trials on Pre-Surgery Survey
-
Johns Hopkins Bloomberg School of Public HealthMakerere University; Institute of Epidemiology, Disease Control and ResearchCompletedNoncommunicable Diseases | Surveys and QuestionnairesBangladesh, Uganda
-
Pacific Northwest University of Health SciencesHealth Resources and Services Administration (HRSA)TerminatedKnowledge, Attitudes, Practice | Self-AssessmentUnited States
-
Children's Mercy Hospital Kansas CityCompletedCongenital Heart Disease | Adherence, Patient | Development, ChildUnited States
-
University of Colorado, DenverCompleted
-
Linkoeping UniversityOstergotland County Council, SwedenCompletedSpinal Stenosis | Lumbar Spine Disc Herniation | Spondylolisthesis, Grade 4Sweden
-
George Washington UniversityCompleted
-
University of HaifaEmek Medical CenterCompletedOsteoarthritis, KneeIsrael
-
New York Medical CollegeTerminatedNecrotizing Soft Tissue InfectionUnited States
-
Sheffield Teaching Hospitals NHS Foundation TrustCompletedObesity | Psychological DisordersUnited Kingdom
-
Oslo University HospitalUniversity of BergenCompletedHeart Defects, Congenital | Hypoplastic Left Heart SyndromeNorway